The predictive markers identified by EGNF across the three datasets—IDH-wt glioma, normal-tumor breast cancer, and HER2-negative breast cancer treated with Bevacizumab—exemplify the model’s ability to uncover biologically significant genes within complex expression networks. This evidence concerns the gene ERBB2 and breast carcinoma.